NewAmsterdam Pharma Company NAMS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's retained earnings?
- NewAmsterdam Pharma Company (NAMS) reported retained earnings of -$810.83M in Q1 2026.
- How has NewAmsterdam Pharma Company's retained earnings changed year-over-year?
- NewAmsterdam Pharma Company's retained earnings decreased by 35.6% year-over-year, from -$598.1M to -$810.83M.
- What is the long-term trend for NewAmsterdam Pharma Company's retained earnings?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's retained earnings has grown at a 75.9% compound annual growth rate (CAGR), from -$140.04M to -$762.39M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.